• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

pSividia eyes knee market, releases earnings

September 10, 2015 By Fink Densford

pSivida

pSivida (NSDQ:PSDV) released its fiscal year earnings for 2015 yesterday and said it’s eyeing an entrance into the orthopedic knee market with a new drug-device implant.

The company said it is slated to submit an investigational new drug application with the FDA and begin a study of a new implant using its Durasert technology to treat severe osteoarthritis pain in the knee.

Psivida claims the new device would be surgically implanted in the knee and provide sustained delivery of a corticosteroid directly to the joint for approximately 6 months.

“With over 10 million cases of knee osteoarthritis and 700,000 knee replacement surgeries last year in the U.S. alone and a population that is aging and increasingly overweight, a product that would offer a new treatment alternative for the pain of severe osteoarthritis of the knee would be a very welcome clinical development,” CEO Dr. Paul Ashton said in prepared remarks.

For the quarter, pSivida reported losses of $5.1 million, or 17¢ per share, on sales of $409,000 for the 3 months ended June 30.

That amounts to a 29.7% increase in losses on sales growth of 40.1% compared to the same period last year. Losses per share were off from analysts expectations by 4¢ for the quarter.

For the year, the company reported profits of $6.3 million, or 22¢ per share, on $25.6 million worth of revenue for the fiscal year ended June 30.

That amounts to an enormous transition from a $13.4 million loss reported last year, and sales growth of over 600% compared to last year. Earnings per share beat estimates with analysts expecting a loss of 45¢.

Shares have stayed steady with the news, rising a slim 0.3% as of mid-day trading.

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: pSivida Corp.

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS